Strong data for Metabasis' HBV drug

26 March 2006

US drugmaker Metabasis Therapeutics has welcomed encouraging Phase II study data on pradefovir, its oral antiviral product candidate, which it licensed to Valeant Pharmaceuticals.

Valeant is evaluating the safety and efficacy of the agent for the treatment of compensated chronic hepatitis B. Data from the Phase II open-label, randomized, multiple-dose, 242-patient study showed that the percentage of patients in the 30mg pradefovir cohort achieving undetectable hepatitis B virus DNA (<400 c/mL) was almost double that of patients receiving 10mg (QD) of Hepsera, a non-liver targeted pro-drug of adefovir, linked to kidney toxicity at doses over 30mg.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight